Retrospective multi-center study of Adolescent and Young Adult (AYA) Multiple Myeloma in Kansai Myeloma Forum registry.


Journal

International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 05 03 2020
accepted: 02 09 2020
revised: 27 08 2020
pubmed: 23 9 2020
medline: 11 11 2020
entrez: 22 9 2020
Statut: ppublish

Résumé

We retrospectively analyzed the clinical features and outcomes in a real-world cohort of adolescents and the young adult (AYA) patients (age between 16 and 39 years) with symptomatic multiple myeloma (MM) registered with the Kansai Myeloma Forum. 26 patients had been diagnosed as symptomatic MM out of 3284 patients. The prevalence of AYA-MM was 0.8% in this cohort. 81% of the patients was received stem cell transplantation, which may improve outcome. Anemia and hypercalcemia might be prognostic factors, however International Staging System failed to predict overall survival. Five patients developed late-onset adverse events which were serious and life-threatening. The 5-year overall survival was 71.0%. We need to develop the new strategy to overcome AYA-MM.

Identifiants

pubmed: 32959221
doi: 10.1007/s12185-020-02996-6
pii: 10.1007/s12185-020-02996-6
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

435-438

Auteurs

Aya Nakaya (A)

First Department of Internal Medicine, Kansai Medical University Medical Center, 10-15 Fumizono-cho, Moriguchi, Osaka, 570-8507, Japan. nakaya1016@yahoo.co.jp.
Kansai Myeloma Forum, Osaka, Japan. nakaya1016@yahoo.co.jp.

Takae Kohara (T)

Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Kansai Myeloma Forum, Osaka, Japan.

Hirohiko Shibayama (H)

Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Kansai Myeloma Forum, Osaka, Japan.

Yoshiyuki Onda (Y)

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kansai Myeloma Forum, Osaka, Japan.

Junya Kanda (J)

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kansai Myeloma Forum, Osaka, Japan.

Hitomi Kaneko (H)

Department of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
Kansai Myeloma Forum, Osaka, Japan.

Kazunori Imada (K)

Department of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
Kansai Myeloma Forum, Osaka, Japan.

Toru Kida (T)

Department of Internal Medicine (Hematology), Toyonaka Municipal Hospital, Osaka, Japan.
Kansai Myeloma Forum, Osaka, Japan.

Satoru Kosugi (S)

Department of Internal Medicine (Hematology), Toyonaka Municipal Hospital, Osaka, Japan.
Kansai Myeloma Forum, Osaka, Japan.

Jun Ishikawa (J)

Department of Hematology, Osaka International Cancer Institute, Osaka, Japan.
Kansai Myeloma Forum, Osaka, Japan.

Ryosuke Yamamura (R)

Department of Hematology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
Kansai Myeloma Forum, Osaka, Japan.

Yutaka Shimazu (Y)

Department of Hematology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.
Kansai Myeloma Forum, Osaka, Japan.

Hirokazu Tanaka (H)

Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka, Japan.
Kansai Myeloma Forum, Osaka, Japan.

Shin-Ichi Fuchida (SI)

Department of Hematology, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto, Japan.
Kansai Myeloma Forum, Osaka, Japan.

Yuji Shimura (Y)

Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural, University of Medicine, Kyoto, Japan.
Kansai Myeloma Forum, Osaka, Japan.

Miki Kiyota (M)

Department of Hematology, Matsushita Memorial Hospital, Osaka, Japan.
Kansai Myeloma Forum, Osaka, Japan.

Katsuya Wada (K)

Department of Hematology, Matsushita Memorial Hospital, Osaka, Japan.
Kansai Myeloma Forum, Osaka, Japan.

Tomoki Ito (T)

First Department of Internal Medicine, Kansai Medical University Medical Center, 10-15 Fumizono-cho, Moriguchi, Osaka, 570-8507, Japan.
Kansai Myeloma Forum, Osaka, Japan.

Nobuhiko Uoshima (N)

Department of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
Kansai Myeloma Forum, Osaka, Japan.

Hideo Yagi (H)

Department of Hematology and Oncology, Nara Prefecture General Medical Center, Nara, Japan.
Kansai Myeloma Forum, Osaka, Japan.

Satoshi Yoshihara (S)

Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan.
Kansai Myeloma Forum, Osaka, Japan.

Kensuke Ohta (K)

Hematology Ohta Clinic, Osaka, Japan.
Kansai Myeloma Forum, Osaka, Japan.

Chihiro Shimazaki (C)

Department of Hematology, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto, Japan.
Kansai Myeloma Forum, Osaka, Japan.

Masayuki Hino (M)

Kansai Myeloma Forum, Osaka, Japan.

Akifumi Takaori-Kondo (A)

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kansai Myeloma Forum, Osaka, Japan.

Junya Kuroda (J)

Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural, University of Medicine, Kyoto, Japan.
Kansai Myeloma Forum, Osaka, Japan.

Itaru Matsumura (I)

Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka, Japan.
Kansai Myeloma Forum, Osaka, Japan.

Yuzuru Kanakura (Y)

Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Kansai Myeloma Forum, Osaka, Japan.

Shosaku Nomura (S)

First Department of Internal Medicine, Kansai Medical University Medical Center, 10-15 Fumizono-cho, Moriguchi, Osaka, 570-8507, Japan.
Kansai Myeloma Forum, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH